Albireo Pharma, Inc. (ALBO)
ALBO Price and Sentiment
ALBO Latest news
– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan2021-10-12 08:30
– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC). Established in 2019, PFIC Awareness Day aims to highlight the impact of this disease on patients and families, and to call for new levels of support, including research, advocacy, education and opportunities to connect and share information.
– Listed on the German national price list and all pharmacy software programs –
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 15,000 shares of Albireo's common stock and restricted stock units representing the opportunity to acquire 3,500 shares of Albireo's common stock. The exercise price for the inducement grants is $29.50 per share, the closing price of Albireo's common stock on September 7, 2021, the grant date, and were granted as inducements material to the employee's acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee's continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee's start date with Albireo and 75 percent in 12 equal quarterly instal
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –
Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of the Company's management team will be presenting at the following investor conferences:
The expectation is that Mirum trades two-fold higher or more on regulatory approval of maralixibat for Alagille syndrome, and better than Albireo's lackluster share price performance post-regulatory successes in PFIC.
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region2021-08-18 01:30
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –